Supriya Lifescience Limited reported Q2 FY '27 revenue of INR206 crores, up 3.2% year-on-year, while EBITDA was INR45 crores with a 22% margin. It lowered FY '27 EBITDA margin guidance to 23% - 25% due to LATAM regulatory changes, Ambernath ramp-up costs and higher input prices.

7 source passages

Supriya Lifescience Limited For Q2 FY '27, the company reported revenue from operations of INR206 crores as against INR200 crores in Q2 FY '26, a growth of 3.2% year-on-year. EBITDA for the quarter stood at INR45 crores as against INR73 crores in Q2 FY '26 while EBITDA margin stood at 22% for Q2 FY '27. we are revising our EBITDA margin guidance downwards to 23% - 25%. Firstly, the regulatory changes in LATAM market affected demand for some of our higher-margin products. Secondly, we incurred higher operating expenses at our Ambernath facility, which is currently in the ramp-up phase. Thirdly, due to the ongoing war and geopolitical tensions, raw material and solvent prices remained high, which has also impacted on our margins during the quarter. Open the document at this passage

Aug 14

Earnings call

Q1 2027 earnings call AI summary on its way

May 28

Earnings call

Q4 2026 earnings call AI summary on its way

Feb 10

Earnings call

Q3 2026 earnings call AI summary on its way

Showing 1–4 of 4 documents